US FDA finalizes expedited access pathway for devices addressing unmet medical needs
This article was originally published in SRA
The US Food and Drug Administration has finalized a new, voluntary program to that aims to speed up the regulatory evaluation of medical devices that can potentially address unmet medical needs for life threatening or irreversibly debilitating diseases1.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.